Implicity centralizes data from connected medical devices


Implicit gear up. Three years after its seed of 4 million euros, the MedTech closes a series A to the tune of 21 million euros thanks to the support of Crédit Mutuel Innovation, Bpifrance, as well as historical investors Serena Capital, XAnge, Karista and BNP Paribas Development. A sum which should, among other things, enable it to accelerate the marketing of its cardiac remote monitoring platform, in France and internationally. The startup also intends to expand the use cases to which the latter can respond. For the record, it was crowned during the first call for projects of the Health Data Hub, the health data platform set up by the government to centralize existing databases on patients and facilitate their use. for research and development purposes. Implicity provides cover “more than 60,000 patients in 100 medical establishments in Europe and the United States”.

The context

Founded in 2016, Implicity was created under the leadership of Arnaud Rosier. This doctor, who wanted to improve the care of patients suffering from cardiovascular disorders, then highlighted the fact that “more than 500,000 people in France are equipped with implantable heart prostheses [pacemakers et défibrillateurs, N.D.L.R.]making this type of material the most widely used medical devices”. Home monitoring has been made possible by the advent of telemedicine. However, the founder of MedTech said he regretted that the fact that we identify “five manufacturers of this type of device in the world” – namely the Americans Abbott, Boston Scientific, the Irish Medtronic, the Chinese Microport and the French Biotronik – involved, for healthcare professionals, using five distinct proprietary platforms on a case-by-case basis. By creating Implicity, Arnaud Rosier sought to set up a universal platform capable of bringing together information from all of these devices – regardless of the brand – in one place.

What will this series A be used for?

The startup recently received clearance from the Food and Drug Administration (FDA) to bring an artificial intelligence algorithm to analyze electrocardiograms from implantable heart monitors to market. Its objective is twofold, in its words: “Provide healthcare professionals around the world with a more holistic approach to cardiac patient care and democratize remote cardiac care. » Implicity will leverage its Series A to expand its presence in the United States, as well as expand into new market opportunities through the development of new software medical devices to further its technological lead. “As monitoring teams grapple with an increasing amount of data from connected devices, the need for a universal remote platform is now widely recognized as paramount” judged in a press release Arnaud Rosier.

We wish to give thanks to the author of this write-up for this remarkable web content

Implicity centralizes data from connected medical devices

We have our social media profiles here , as well as other related pages here